Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$2.8 million.

  • Beam Therapeutics' Other Non Operating Income fell 127850.0% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522000.0, marking a year-over-year increase of 440.0%. This contributed to the annual value of $2.3 million for FY2024, which is 6970.67% down from last year.
  • Beam Therapeutics' Other Non Operating Income amounted to -$2.8 million in Q3 2025, which was down 127850.0% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Other Non Operating Income peaked at $35.8 million during Q3 2021, and registered a low of -$42.3 million during Q2 2021.
  • Over the past 5 years, Beam Therapeutics' median Other Non Operating Income value was $1.1 million (recorded in 2025), while the average stood at $1.8 million.
  • In the last 5 years, Beam Therapeutics' Other Non Operating Income soared by 122592.59% in 2021 and then tumbled by 127850.0% in 2025.
  • Quarter analysis of 5 years shows Beam Therapeutics' Other Non Operating Income stood at $7.4 million in 2021, then tumbled by 59.46% to $3.0 million in 2022, then crashed by 163.33% to -$1.9 million in 2023, then surged by 93.26% to -$128000.0 in 2024, then crashed by 2053.91% to -$2.8 million in 2025.
  • Its last three reported values are -$2.8 million in Q3 2025, $1.1 million for Q2 2025, and $2.3 million during Q1 2025.